Nature Reviews Genetics, Journal Year: 2023, Volume and Issue: 25(1), P. 8 - 25
Published: Aug. 24, 2023
Language: Английский
Citations
132Imputation accuracy across global human populations
The American Journal of Human Genetics, Journal Year: 2024, Volume and Issue: 111(5), P. 979 - 989
Published: April 10, 2024
Language: Английский
Citations
8Protective alleles and precision healthcare in crewed spaceflight
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: July 22, 2024
Abstract Common and rare alleles are now being annotated across millions of human genomes, omics technologies increasingly used to develop health treatment recommendations. However, these have not yet been systematically characterized relative aerospace medicine. Here, we review published naturally found in cohorts that a likely protective effect, which is linked decreased cancer risk improved bone, muscular, cardiovascular health. Although some technical ethical challenges remain, research into mechanisms could translate nutrition, exercise, recommendations for crew members during deep space missions.
Language: Английский
Citations
7A Systematic Review of Family History, Race/Ethnicity, and Genetic Risk on Prostate Cancer Detection and Outcomes: Considerations in PSA-based Screening
Urologic Oncology Seminars and Original Investigations, Journal Year: 2024, Volume and Issue: 43(1), P. 29 - 40
Published: July 15, 2024
Language: Английский
Citations
4Equitable machine learning counteracts ancestral bias in precision medicine
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: March 10, 2025
Gold standard genomic datasets severely under-represent non-European populations, leading to inequities and a limited understanding of human disease. Therapeutics outcomes remain hidden because we lack insights that could be gained from analyzing ancestrally diverse data. To address this significant gap, present PhyloFrame, machine learning method for equitable precision medicine. PhyloFrame corrects ancestral bias by integrating functional interaction networks population genomics data with transcriptomic training Application breast, thyroid, uterine cancers shows marked improvements in predictive power across all ancestries, less model overfitting, higher likelihood identifying known cancer-related genes. Validation fourteen demonstrates is better able adjust ancestry populations. The ability provide accurate predictions underrepresented groups, particular, substantially increased. Analysis performance the most continental group, African, illustrates how phylogenetic distance negatively impacts performance, as well PhyloFrame's capacity mitigate these effects. These results demonstrate artificial intelligence (AI) approaches can contribute representation medical research. Ancestral cancer limits effectiveness Here, authors introduce framework adjusts disease signatures based on data, improve medicine ancestries cancers.
Language: Английский
Citations
0Harnessing the Power of Discovery
Cancer Discovery, Journal Year: 2023, Volume and Issue: 13(4), P. 819 - 823
Published: March 8, 2023
Summary: Cancer Grand Challenges is an international funding initiative that aims to unite the world's best scientists tackle some of cancer's toughest challenges by team science on a global scale. Here, we discuss nine new, ambitious currently open for application.
Language: Английский
Citations
9Prostate cancer metastasis and health disparities: a systematic review
Prostate Cancer and Prostatic Diseases, Journal Year: 2023, Volume and Issue: 27(2), P. 183 - 191
Published: April 12, 2023
Language: Английский
Citations
8Understanding inequities in precision oncology diagnostics
Nature Cancer, Journal Year: 2023, Volume and Issue: 4(6), P. 787 - 794
Published: May 29, 2023
Language: Английский
Citations
7Global viewpoints: updates on prostate cancer in
BJU International, Journal Year: 2023, Volume and Issue: 133(1), P. 6 - 13
Published: Sept. 13, 2023
Prostate cancer (PCa) is a major health concern in Sub-Saharan Africa (SSA), with high incidence and mortality rates. However, the widely used prostate-specific antigen (PSA) screening not readily available or affordable SSA. Alternative strategies, such as risk stratification approaches cost-effective PSA tests, are being explored to target high-risk individuals improve access screening. Diagnosis of PCa SSA challenging due lack diagnostic tools limited healthcare resources. Clinical evaluation digital rectal examination commonly used, but testing, magnetic resonance imaging, biopsy often limited. As result, many men diagnosed at advanced stages disease. Treatment options for by resources trained providers. Surgery, radiation therapy, androgen-deprivation therapy may be inaccessible patients. Cultural beliefs stigma surrounding further impact treatment decisions. Improved patient community awareness, electronic medical records, communication between patients professionals can enhance evidence-based decision-making advocate policy changes. Understanding genetic determinants implementing comprehensive strategies lead improved outcomes better control
Language: Английский
Citations
7Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS‐plus, 1990–2019: A comparable study of key nations with emerging economies
The Prostate, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 8, 2024
Abstract Backgrounds The study aimed to analyze epidemiology burden of male prostate cancer across the BRICS‐plus, and identify potential risk factors by assessing associations with age, period, birth cohorts sociodemographic index (SDI). Methods Data were extracted from Global Burden Disease Study 2019. average annual percent change (AAPC) was calculated assess long‐term trends, age‐period‐cohort analysis used these three effects on burden. Quantile regression investigate association between SDI health outcomes. Results higher incidence mortality observed in Mercosur SACU regions, increasing trends almost all BRICS‐plus countries (AAPC > 0), EEU's grew 24.31% (%AAPC range: ‐0.13–3.03). Mortality had increased more than half 1.82% 0.62–1.75). Incidence sharply age globally, peak reached group 80–84 years. Rate ratio (RR) except for Kazakhstan where slightly decrease, while RR decreased cohort most countries. presented significantly positive 50 percentiles. deaths attributable smoking declined nations, many China‐ASEAN‐FTA EEU values. Conclusion Prostate posed a serious public challenge an among Age significant burden, recent suffered risk. relationship incidence, smoking‐attributable tremendous region. Secondary prevention should be prioritized policies targeting important populations strengthened based their characteristics adaptability.
Language: Английский
Citations
2